HomeCompareVXEL vs ABBV

VXEL vs ABBV: Dividend Comparison 2026

VXEL yields 1129.94% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VXEL wins by $55106566.56M in total portfolio value
10 years
VXEL
VXEL
● Live price
1129.94%
Share price
$0.18
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$55106566.66M
Annual income
$46,935,440,022,475.77
Full VXEL calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — VXEL vs ABBV

📍 VXEL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVXELABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VXEL + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VXEL pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VXEL
Annual income on $10K today (after 15% tax)
$96,045.20/yr
After 10yr DRIP, annual income (after tax)
$39,895,124,019,104.41/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, VXEL beats the other by $39,895,123,998,048.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VXEL + ABBV for your $10,000?

VXEL: 50%ABBV: 50%
100% ABBV50/50100% VXEL
Portfolio after 10yr
$27553283.38M
Annual income
$23,467,720,023,623.77/yr
Blended yield
85.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VXEL
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VXEL buys
0
ABBV buys
0
No recent congressional trades found for VXEL or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVXELABBV
Forward yield1129.94%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$55106566.66M$102.3K
Annual income after 10y$46,935,440,022,475.77$24,771.77
Total dividends collected$54492347.73M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VXEL vs ABBV ($10,000, DRIP)

YearVXEL PortfolioVXEL Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$123,694$112,994.35$11,550$430.00+$112.1KVXEL
2$1,438,592$1,306,239.51$13,472$627.96+$1.43MVXEL
3$15,737,287$14,197,992.90$15,906$926.08+$15.72MVXEL
4$161,994,985$145,156,088.52$19,071$1,382.55+$161.98MVXEL
5$1,569,777,558$1,396,442,923.94$23,302$2,095.81+$1569.75MVXEL
6$14,326,325,309$12,646,663,321.80$29,150$3,237.93+$14326.30MVXEL
7$123,196,235,490$107,867,067,408.90$37,536$5,121.41+$123196.20MVXEL
8$998,717,416,634$866,897,444,660.21$50,079$8,338.38+$998717.37MVXEL
9$7,636,566,950,701$6,567,939,314,902.11$69,753$14,065.80+$7636566.88MVXEL
10$55,106,566,659,726$46,935,440,022,475.77$102,337$24,771.77+$55106566.56MVXEL

VXEL vs ABBV: Complete Analysis 2026

VXELStock

HWGC Holdings Limited, through its subsidiaries, operates as a direct selling and multi-level marketing company primarily in Malaysia. It offers travel, entertainment, lifestyle, and other products and services primarily through electronic commerce. The company operates Vionmarket, a rebate website that provides retail sales direct to consumers; VTrips, a platform that offers concessionary and travel packages; and VMall, an e-commerce platform. The company was formerly known as Vitaxel Group Limited. HWGC Holdings Limited is based in Kuala Lumpur, Malaysia.

Full VXEL Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VXEL vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VXEL vs SCHDVXEL vs JEPIVXEL vs OVXEL vs KOVXEL vs MAINVXEL vs JNJVXEL vs MRKVXEL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.